
This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
By Daniel McCallum Comments are off
This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
Tagged with: Celltrion, Featured, Hospira, Infliximab, Janssen, Legal, Litigation Spotlight, Remicade®
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...
Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Spencer Johnson Comments are off
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Seth Cockrum Comments are off
As previously reported, earlier this year Celltrion, Inc. (“Celltrion”) filed petitions seeking inter partes review (“IPR”) of...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Seth Cockrum Comments are off
As we previously reported, Celltrion filed three petitions seeking inter partes review (“IPR”) of two patents related to Genentech and...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Andrew Storaska Comments are off
Samsung Bioepis (“Bioepis”) has joined a growing list of challengers to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213...
Tagged with: Boehringer Ingelheim, Celltrion, Genentech, Herceptin®, IPR, Legal, Mylan, News, Pfizer, Samsung Bioepsis, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Amgen and Allergan recently announced that they submitted a Biologics License Application (“BLA”) for ABP 980, a proposed biosimilar to...
Tagged with: Allergan, Amgen, Biocon, Celltrion, FDA, Genentech, Herceptin®, Hospira, Mylan, News, Pfizer, Regulatory, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Celltrion announced last week that its Biologics License Application (“BLA”) for CT-P10, a biosimilar to Biogen and Genentech’s...
ShareEmail, Linked In, Twitter, Facebook, Google Plus